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ARTICLE
Improving the informed consent process in
international collaborative rare disease research:
effective consent for effective research
Sabina Gainotti*,1,9, Cathy Turner2, Simon Woods3,9, Anna Kole4,9, Pauline McCormack3,9,
Hanns Lochmüller2,9, Olaf Riess5, Volker Straub2, Manuel Posada6,9, Domenica Taruscio1,9 and
Deborah Mascalzoni7,8,9
The increased international sharing of data in research consortia and the introduction of new technologies for sequencing challenge
the informed consent (IC) process, adding complexities that require coordination between research centres worldwide. Rare disease
consortia present special challenges since available data and samples may be very limited. Thus, it is especially relevant to ensure
the best use of available resources but at the same time protect patients’ right to integrity. To achieve this aim, there is an ethical
duty to plan in advance the best possible consent procedure in order to address possible ethical and legal hurdles that could hamper
research in the future. Therefore, it is especially important to identify key core elements (CEs) to be addressed in the IC documents
for international collaborative research in two different situations: (1) new research collections (biobanks and registries) for which
information documents can be created according to current guidelines and (2) established collections obtained without IC or with
a previous consent that does not cover all CEs. We propose here a strategy to deal with consent in these situations. The principles
have been applied and are in current practice within the RD-Connect consortia – a global research infrastructure funded by the
European Commission Seventh Framework program but forward looking in terms of issues addressed. However, the principles
established, the lessons learned and the implications for future research are of direct relevance to all internationally collaborative
rare-disease projects.
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INFORMED CONSENT FOR RARE DISEASE RESEARCH IN THE
ERA OF GLOBAL DATA SHARING AND NEXT-GENERATION
SEQUENCING
Fostering global data sharing that allows collaborative work on scarce
and disparate resources is essential for research into rare diseases (RDs).1
The challenges posed by new sequencing technologies and the world-
wide dimension of data sharing require research consortia to adapt
existing informed consent (IC) procedures to a new reality and ensure that
consent processes are relevant and useful for ongoing and new collections.
For RD patients, research is often the only hope for future
treatments and in some cases the only possibility for getting
a diagnosis. This creates a status of special vulnerability in RD patients
that could lead them to accept conditions which they might not in
other circumstances. Therefore, it is especially important to identify
guidance that will foster the right to enjoy the benefits of scientific
progress for RD patients and at the same time respect patients’ rights
and values:2–7 we regard it as an ethical duty to plan ahead the best
possible consent procedures in order to anticipate and avoid ethical
and legal hurdles that could hamper research in the future.
RD-Connect is a global research infrastructure8 aimed at developing
an integrated platform in which omics data will be combined with
clinical phenotype information and biomaterial from multiple RD
projects including EURenOmics9 and NeurOmics.10
We suggest that RD-Connect poses relevant ethical challenges,
which are common to other international research projects focused
on omics research and can therefore be used to learn common lessons.
There are sensitive topics that need special consideration in the
consent process such as return of incidental findings to participants;
the ties to family members and possible obligations arising from
research results; the future use of samples; the limits or the foreseen
sharing of data derived from next-generation sequencing (NGS);11 as
well as the difficulty to explain and enforce the right to withdraw from
research in the light of global sharing. The very nature of genomic
research promotes a widespread dissemination and ongoing reuse of
data and participants should be made aware that different actors and
bodies (ie, research ethics committees (RECs), internal governing
boards and external reviewers) will be responsible to decide on their
behalf for future uses and for reviewing and evaluating access requests
from external researchers.12–14 This means that the protection of their
integrity is delegated to a system that should be explained and
disclosed.12–14
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In fact specific features of omics research, and in this case of the
global RD-Connect platform, raise particular challenges for the IC
process as they add new ethical and legal complexities and require
coordination and harmonisation between different research centres
worldwide.15–17
IC is traditionally discussed in terms of its function as a means
to ensuring respect for personal autonomy, integrity, self determina-
tion and the right to privacy.18
In RD research respecting privacy can be especially challenging
since, in certain cases, it would suffice to link basic information like
the name of the disease and the name of the treating physician or the
specific ultra-rare sequence change and the place of origin to trace
back individual patients.19–22 In ‘undiagnosed cases’ clinical and
genetic data (and occasionally also patient images) are often entered
into databases expressly conceived to facilitate the matching of cases
with similar phenotypic and genotypic profiles (eg, the Matchmaker
Exchange project http://www.matchmakerexchange.org/).
Family contact and therefore re-identification is common practice
to build a full data set, and it is often necessary to be able to re-contact
and re-identify patients. This is usually accepted by patients and
relatives because it is only through the promotion of research that they
will progress towards a diagnosis or a cure,23 but requires that
participants are carefully informed of the risk as codification cannot
ensure a zero risk of re-identification.22
To address those special concerns we tried to determine the kind
of information that should be required for this type of research
in international consortia in the form of core elements (CEs) required
for informing patients in research.
The CEs recommended in our guidelines are in response to
particular legal and ethical requirements identified through an extensive
literature analysis and on the values identified through stakeholder
involvement.
Key values identified by stakeholders at a workshop held in Rome in
April 2014 with patients, scientists, industry and ethicists include:
1. Respect for patients’ and patients’ families’ integrity;
2. The right to enjoy the benefits of scientific advancement;
3. Altruism and solidarity.24
All such values are assumed to hold within an environment where
trust is well-placed.25 RD research is often conducted in a context
in which the research is closely tied to patient care and is merged
in the route to diagnosis. The current request made by key funders for
research to be conducted in the international context of data sharing,
possibly with unspecified partners, may not always be clear enough
to patients. The link between research and this close, clinical
relationship should be made transparent and explicit so respecting
the special trust granted by participants.26
Also, participants should be offered the possibility to decide the level
of accessibility of their data, especially in matchmaking databases where
researchers must decide to make a case ‘private’ (visible and accessible
only by themselves), ‘matchable’ (visible by all users and accessible
upon request) and ‘public’ (visible and accessible by all users).
The discussed sharing practice can get really problematic if it does
not also include an explicit sharing of responsibilities, which could
be facilitated through the adoption of a ‘Code of Conduct’ and
a system of unique identifiers for researchers.27 Researchers not
directly involved in a caring relationship with the RD patient might
perceive that they are not bound by the same medical or deontological
framework as are treating clinicians.
INFORMED CONSENT FOR NEW RESEARCH COLLECTIONS
In the last decade, there has been a shift from a specific IC
paradigm to a paradigm that tries to take into account the values
of beneficence, solidarity, justice, reciprocity, mutuality, citizenship
and universality.28–33
Different models such as broad consent and dynamic consent have
been proposed as possible solutions to some of the ethical challenges
described above, like future uses and international sharing of samples
and data derived from NGS, return of incidental findings to
participants and family members and difficulty to enforce the right
to withdraw from research.34–37
Focus groups carried out with RD patient representatives (http://rd-
connect.eu/platform/ethics/rd-pec/)38 highlighted that RD patients
generally find acceptable broadly described purposes for the use
of biomaterials and data for biobanks. However, many would prefer
to see access to their data more strictly controlled. Also, RD patients
foresaw a number of possible risks for themselves, their children and/
or other family members; most notably discrimination in such areas
as employment, health-care access and financial matters.
Therefore, we propose that if broadly descriptive consent is to be
adopted, then this should be supplemented by providing partici-
pants with additional safeguards and opportunities for being
updated.39 Patients may accept data sharing and find broadly
described purposes of a research acceptable, provided there is
clarity about governance of data and samples, re-contact policies,
privacy measures, ethical oversight, clear withdrawal policy and a
commitment to keep participants informed if major changes in
these areas occur.
For RD patients, research is often the only hope for future treatments
and in some cases the only possibility for getting a diagnosis, and RD
patients and their families are usually highly motivated to participate
and have a significant role in the research process. The need to
re-contact and involve patients in research takes advantage of patient-
centric approaches to consent that provide dynamic interaction
exploiting online technologies to help address new challenges. Online
tools can assist with ongoing information and participant involvement
regarding new studies.40,41
During the IC process, new research participants as well as
participants who are re-consenting are entitled to understand to what
extent they are involved in research and the kind of control that is
granted to them on the use of their data and samples.
The challenges of this procedure are on many levels and include the
need to explain genomic research in simple language as well as to
provide information about the potential foreseeable uses of data and
samples.11,42,43
It is therefore important that:
 Researchers make a sincere attempt to provide clear information
in patient friendly form and include the CEs (as defined below);
 Information is provided to patients at least when major changes
occur and by sharing general results (brochures, colloquium,
internet pages, mass media);
 The formal decision (consent) should take place after the informa-
tion process, allowing participants appropriate time to think, reflect
and ask questions;
 A description of the communication of information strategy for the
future (after the collection) is provided to the participant;
 Wherever possible patient/participant representatives are consulted
on the quality, detail and clarity of the information provided before
a study starts.
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CORE INFORMATION ELEMENTS
There are some essential requirements for a valid IC,17,44,45 including
age and legal capacity of the participant, freedom of choice and
voluntariness – implying the right to withdraw from research at any
moment without prejudice. IC in human research must clearly
describe research objectives, procedures, risks involved and expected
benefits to potential participants. As voluntariness is a precondition
of participation in research and IC aims to support a free informed
decision, the elements that mostly impact the risk/benefit ratio of the
project should always be disclosed.
A broad description of the kind of research expected at the time
of the collection is acceptable, provided transparent information about
the CEs is provided.
CEs should be included in the IC material for ongoing and future
collections occurring in global consortia46,47 (Box 1):
1. Study procedure: descriptions should address how and for how
long the storage and conservation of samples and data is planned;
access policies; security measures; the use and sharing of the data
for research; and information on options for future uses.
2. Reasonably anticipated benefits: participants are made aware that
there will probably be no direct personal benefits, though it might
be reasonable to describe potential secondary benefits, for example,
in the case of registries, participants may be kept up-to-date about
ongoing clinical trials for their RD. Also, participants without a
clear diagnosis may benefit in terms of advancing knowledge on the
causes of their condition and possibly find the causative gene.
3. Foreseeable informational risks: these include the potential loss
of confidentiality caused by misuse of data, misconduct, hacking,
the chance of information about a family member being divulged
in one's country and abroad, also in jurisdictions that may have
different data protection provisions in place. The current evidence
does not allow us to draw conclusions about the efficacy of de-
identification methods;48 therefore, participants should be aware
that their data will be accessed, shared and linked to other sets of
information, that there exist different data protection regulations
in different countries and that, while all reasonable efforts will be
made to protect confidentiality, the purpose and extent of further
usage cannot be foreseen. Participants should be made aware
specifically if their medical records will be accessed and how these
may be used alongside data from research studies.
4. International data sharing: in a research scenario where the data are
shared widely and frequently, the sharing process must be clearly
described. Several studies show that research participants across a
range of populations and disease groups wish to be informed
whether wide data-sharing procedures are implemented.49,50 Parti-
cipants should be informed that their coded data will be placed in
international archives such as the European Genome-phenome
Archive (EGA), where access to data will be overseen and decided
by a data access committee according to established principles and
criteria. Information on the use of interoperable identifiers allowing
matching between different databases also needs to be provided.
Interoperable identifiers, created by using the same data elements in
different databases with different algorithms will enable researchers
to follow patients over time and across diseases, registries, studies
and countries and avoid duplicating efforts by matching data
collected at different times and by different entities, including
linking patients’ clinical information recorded in registries to
biological samples available in one or more biobanks.
5. Use of NGS techniques: participants must be informed that their
samples are likely to be analysed using large-scale genome
sequencing techniques that carry potential for clinically relevant
discoveries for individuals and families. A brief description of the
techniques used should be given and the aim of the analysis
explained, including the possibility of discovering previously
unknown mutations relating to their condition as well as ‘disease
modifier’ genes which do not directly cause the condition but
might affect its severity and its course.
6. Return of secondary findings and access to sequences: this is a very
sensitive issue that needs to be addressed.51 As there are no shared
guidelines on this matter the IC should at least state if return is
Box 1 Essential elements of IC documents for International
Consortia on RD
Information elements that are relevant in IC documents for biobank and
observational studies in RD Research
 General (name of the PI, Institution, funding, duration, over-
sight, contact persons)
 Aims, research uses of data (eg, cancer research and RD
research)
 Voluntariness of participation and possibility to withdraw
 Procedures involved in participation, including interviews and
blood taking
 Kinds of samples and data that will be collected
 Potential physical, psychological and social risks
(informational risks)
 Potential benefits of participation
 Protections in place locally to ensure the confidentiality of
samples and data
 Access to data/samples for research purposes: who will have
access, who should control and what the procedures in place
(data access committee)
 Access to data/samples for purposes such as validation and
quality control
 Study oversight
 Compensation/reimbursement
 Custodianship of samples
 Study dissemination plans (professional journals/lay versions/
codified or aggregated results only/specific results/patient pic-
tures and occasionally short professional video sequences).
CEs for the IC of studies participating to international RD research
 Possibility of data sharing across research groups and national
borders
 Possibility of large-scale genome sequencing techniques
 Return of secondary findings
 Hosting of the data in open access database (eg, in RD-Connect
the European Genome-Phenome Archive)
 Use of interoperable identifiers for the de-identification of
participants
 Access by industry if foreseen and prospects for third-party
commercialisation and intellectual property
 Possible linkage to different data (registries, medical
records, etc.)
 Withdrawal procedures, such as sample retrieval and/or destruc-
tion and difficulties in ensuring the right to withdraw for the
data already shared
 Permission to re-contact
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planned or not. If not, when sequencing is performed, it should
be clear whether individuals may ask permission to access their
sequencing in order to seek advice elsewhere. If return is planned,
then it should be detailed how the re-contact will occur; if the
health-care system will be involved, then what are the researchers’
options if results have implications for family members. Return of
secondary findings should always be optional and not forced. As it
is unclear to what extent or how secondary findings may impact
individuals in future discoveries, this is a strong argument for
asking the participants if they want to be re-contacted or not.
7. Procedures for data access: Core elements should also include
details of the procedures for data access52 and the persons entitled
to access the data, including industry access with prospects for
third-party commercialisation and intellectual property
procedures.53
8. Right to withdraw: a research participant holds a right to
withdraw from research at any time,18 but wide sharing and
an open research programme create a problem for the
execution of the right to withdraw. It must be acknowledged
therefore that there may be some practical limitations in
respecting the right to withdraw, in particular that while it is
always possible to withdraw and deny access for future research
projects, it may be impossible to withdraw from a specific
research project for which one's data may have already been
accessed.12 The name of the person legally responsible for data
as well as specimen custodianship must be available.
9. Permission to re-contact: permission to re-contact should always
be pursued in order to allow unexpected events to be addressed
in the future. If the project does not ask permission then this
may lead to the impossibility of re-contact in the future.
10. The information strategy on a general level should be described: the
strategy may vary greatly from project to project but it should be
clear whether the plan foresees individual information being
returned or whether the study is planning to publish newsletters,
or information on a webpage dedicated to patients.
We suggest the inclusion of the following items in the IC, as it
seems reasonable and will provide greater flexibility to researchers and
participants:
11. Destination of data and biospecimens after death or in the case
of the termination of the project;
12. Access to research results by family members if foreseen, or
after death.
Participants should preferably be allowed to express choices with
regard to the CEs. CEs are moving targets and the need to re-contact
patients in the future is foreseeable. Therefore, we strongly recom-
mend that permission is sought to be able to re-contact participants
and ask them for contact details. Of course they may freely refuse this
option.
USE OF EXISTING BIOSPECIMENS COLLECTION
The use of biological samples and data outside the purpose originally
described in the consent form is usually considered as 'secondary
use’.54 The original consent, usually describing the aims of the
‘primary use’ of donation and/or data collection may not contemplate
one or more CEs previously defined.17
Given the scarcity of biospecimens in RDs, existing collections are
extremely precious. As such, every effort should be made to use
existing data and samples by looking at feasible ways for preserving
and maximising their use in the future.55,56
In some jurisdictions, institutional review boards/research ethics
committees (IRBs/RECs) can determine whether sharing a partici-
pant’s data for research purposes is consistent with the IC of study
participants from whom the data were originally obtained. However,
IRBs/REC can differ in their decisions even in countries where there is
guidance or legislation.15
In international consortia using RD data and samples we suggest
that, whenever possible, the original IC document used in existing
collections be revised by the local investigator subject to IRB/REC
approval to ensure that IC is compliant. If CEs are missing and
re-contact is feasible (as in the case of regular follow-up visits with the
researcher), then a re-consent is required. This may be done by actively
asking participants’ permission (opt-in) or by sending participants
a notification and a description of the research project and presuming
his/her consent unless s/he declines participation (opt-out).
Although the ‘opt-in’ option is always preferable, there may
be instances in which the request may not be highly sensitive (few
CEs missing in the original IC document), the costs of re-consent may
be considered as too high for researchers in terms of possible drop
outs, the re-contact may involve very old cohorts or the number
of people to be re-consented may be very high. However, this is not
likely to be the case in RD research.
For some cohorts, the researcher may still find re-consent achiev-
able within reasonable efforts, using this also as an opportunity
to update or collect new data. Other projects may be particularly
vulnerable to drop outs and here one may want to use a scheme with
notification and opt-out.
A clear distinction should be made between collections in which
a previous consent was obtained and a question was not asked, and
one where a patient actively declined an option or in which the
information provided excluded some options (eg, ‘your data will not
be shared with any commercial organisations’). In the last instances,
opt-in re-consenting should always be pursued in order to verify
whether these options are now acceptable to the participant.
OPT-IN RE-CONSENT
Opt-in procedures require the participant/donor to actively give
permission. Rare disease research may be particularly vulnerable to
selection bias because the number of available samples and data is
intrinsically low for each condition. However, careful consideration of
the time, effort and other resources required to adequately re-consent
patients should be given, as re-consent may also result in the benefits
of better patient engagement, reducing drop-out rates and increasing
donors’ motivation to participate in research projects. Also, re-consent
would be the occasion to effectively broaden the scope of participants'
consent, thus ensuring its broad validity in future research projects.
An analysis of the costs associated with consent should also include
an examination of the costs of ‘no consent’ or badly designed consent
for the use of samples and information. If research participants feel
that relevant information has been withheld from them, then this may
result in a loss of public trust in research; and therefore, a reduction
in participation in future studies, loss of opportunity for follow-up
and loss of patient organisation support in research projects.57
Some studies indicate that patients are more willing to share their
data when procedures are in place that give them more control over
the way their data are used.58 Establishing a better dialogue about
research with a patient cohort may lead to a more motivated,
informed and proactive patient community.59 Trust and transparency
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may be increased and drop-out rates may reduce, as the NeurOmics
experience illustrates below.
OPT-OUT STRATEGIES
In an opt-out procedure, the participant/donor receives a notification
and a description of the research project and consent is presumed
unless he/she declines participation. Opt-out methods are designed to
minimise the burdens of eliciting IC from a large number of patients
while providing those who do not wish to contribute the opportunity
to exercise that preference60 although studies show that donors/
participants are not always favourable to opt-out schemes.61–63
Therefore, this option may only be justified when re-contact is not
achievable with reasonable efforts.
The fact that opt-out options do not affect research in terms of drop
outs is supported by the report of a Swedish study.64 Recent legislation
in Finland also supports this view, and foresees the implementation
of opt-out options for registries and biobanks.65
WAIVER OF CONSENT
Although having a valid consent in place is the most ethical option,
there are instances in which a waiver may be requested to ethical
boards, especially where it is determined that re-contacting patients
requires disproportionate effort or is impossible (perhaps because of
lack of contact details or patients lost to follow-up). This waiver
should contain an explanation why participants should or could not
be re-contacted. New consent procedures may ensure that this
occurrence will be minimised in the future by asking specific
permission to look up contact information for re-contacting patients.
This option is not feasible in every legal system and requires
an adequate assessment of the reasons for asking for a waiver from the
ethics review board.
The ‘moral endorsement’ of patient organisations could be sought
in order to ensure that the patient community is aware of, and agrees
with, certain uses of data and samples related to their diseases.66
Indeed patient associations often have an educational role, and patient
representatives dedicate a lot of time and efforts to explain to other RD
patients the kind of research that is conducted and highlighting the
importance of participating in clinical and observational research.
Even if re-consent is perceived as burdensome and detrimental
to research by many researchers, positive outcomes can come by its
practice.
THE NEUROMICS EXPERIENCE
The NeurOmics project is facing many of these consent and re-contact
issues now. As a partner project of RD-Connect,10 NeurOmics is
undertaking whole-exome sequencing and deep phenotyping of 1100
genetically-undiagnosed rare neuromuscular and neurodegenerative
disease patients.
NeurOmics has therefore worked closely with RD-Connect in order
to recommend CEs to be included in any consent forms used by
partners contributing samples. Templates were circulated to all
partners collecting samples and data in January 2013. This template
included permission to have samples included in genetic research,
specified how data would be accessed – including by international and
commercial partners, made clear that unrelated findings would not
be returned, asked for permission to re-contact and made clear the
right to withdraw from the research. Partners were asked to check
existing consent forms against this template.
NeurOmics investigators are requested to confirm that the consent
necessary to share data is in place when entering phenotype data into
the project’s clinical database, PhenoTips.67 Where this consent is not
yet obtained, it is expected that patients will be re-contacted and
re-consented following the guidelines proposed here (Figure 1) and
drawn up by RD-Connect, NeurOmics and patient groups.
This has now resulted in the confirmed consent and therefore
possible sharing of data for 976 of 1065 patients entered into the
PhenoTips system. In the meantime, those remaining 89 patients are
being re-contacted according to the proposed guidelines. In spite
Figure 1 Procedures for using already collected samples.
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of time and resource implications, which have understandably been
a concern for partners, this re-contact has worked well and has had
benefits beyond the obtaining of consent.
At the University of Newcastle, patients for whom consent was
incomplete were contacted by telephone and/or letter in order
to explain the changing research needs, data-sharing intentions and
to request consent. This resulted in only one patient declining the
request, around 80% returning new consents and 20% with no
response so far – (still ongoing). Clinicians involved reported added
benefits – up-to-date clinical and family information could
be obtained, patients and their families were generally motivated
to be involved in research, hear more about it and give further samples
if required. Several patients reported that it was good to know that
their (historic) sample was still being used and that they had not been
forgotten. The clinicians were also able to use the contact to answer
questions or concerns and manage patient expectations where
required. The team at Newcastle University feel that this has resulted
in a more engaged patient cohort and have reported this as a very
positive outcome of investing the resources needed to undertake this
updating of consent.
CONCLUDING REMARKS
In the era of genomic research and global data sharing, participants
must deal with an unprecedented mass of information and complex-
ity. Moreover, the information given today may be obsolete in the near
future. The risks and the aims of research and the benefits of
participation are not always completely foreseeable at the time the
data and/or samples are collected.
In this current work we propose that, for the IC of prospective
cases, broadly described research purposes with ongoing updates
for participants is the best current solution. This allows for the
requirement of research to have a flexible tool as well as the need for
transparency and good ethical standards. Achieving a good balance
between the level of understanding that is required for meaningful
IC,11,68 especially for data sharing in genomics, and the need for
practical solutions, is burdensome without a system in place to engage
participants. Therefore, dynamic options may be the future of
research, especially in projects where a share of funding is devoted
to the development of IT platforms.
If this option is not yet implementable, then we propose that
at least:
 Regular updates on development and aggregated results of the
project/biobank are given to participants;
 Patient participation is promoted at a more institutional level by
involving patient organisations in governance, developing policies,
practices and documentation.
Regarding established collections, the decision to ask for re-consent
through active opt-in or opt-out procedures, or to ask for a waiver of
consent from the IRB/REC, should be guided by a careful evaluation
of the following elements:
 Possibility of re-contact and re-consent of patients within a
reasonable effort (also dependent on researchers’ resources, eg,
availability of contact details and possibility to meet the patient
during follow-up visits);
 Specificity of the original IC and number of CEs missing;
 Rarity of the collection and the disease under study;
 Endorsement by patient associations directly involved with the
research and collections at stake.
The process of IC that we propose here is intended to enhance the
involvement of participants, but we are aware that there are instances for
which the applicability is not certain, for example, in very old collections.
The effort to create a good ethical framework for prospective use,
including clear governance and good IC procedures, is an ethical
obligation in the light of good, sound, well-thought procedures that
allow scientific research to happen. Although our emphasis is on good
ethical guidance, we understand that different legal jurisdictions may
require different standards, even though the ethical principles are
broadly applicable across different contexts. But, without doubt, it is
necessary to plan ahead for better consent and ethical practices
in future collections.
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